Search

Your search keyword '"Cascavilla, N."' showing total 416 results
Start Over Author "Cascavilla, N."
416 results on '"Cascavilla, N."'

51. SP232PLASMIC SCORE FOR A QUICK ASSESSMENT OF ADAMTS13 ACTIVITY IN PATIENTS FROM SOUTHERN ITALY WITH THROMBOTIC MICROANGIOPATHIES

Author

Tiscia, G, primary, Cappucci, F, additional, Scalzulli, P, additional, Cascavilla, N, additional, Battista, C, additional, Abrescia, A, additional, Buquicchio, C, additional, Brigante, M, additional, D'Andrea, G, additional, Di Paolo, B, additional, Giordano, G, additional, Infante, B, additional, Piano, S, additional, Ranieri, P, additional, Tullo, L, additional, Ostuni, A, additional, Grandone, E, additional, Aucella, F, additional, and Vergura, Michele, additional

Published
2018
Full Text
View/download PDF

52. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey

Author

Girmenia, C., Bertaina, A., Piciocchi, A., Perruccio, K., Algarotti, A., Busca, A., Cattaneo, C., Raiola, A. M., Guidi, S., Iori, A. P., Candoni, A., Irrera, G., Milone, G., Marcacci, G., Scime, R., Musso, M., Cudillo, L., Sica, Simona, Castagna, Luigi, Corradini, P., Marchesi, F., Pastore, D., Alessandrino, E. P., Annaloro, C., Ciceri, F., Santarone, S., Nassi, L., Farina, C., Viscoli, C., Rossolini, G. M., Bonifazi, F., Rambaldi, A., Capria, S., Mastronuzzi, A., Pagliara, D., Bernaschi, P., Amico, L., Carotti, A., Mencacci, A., Bruno, Brunella, Costa, C., Passi, A., Ravizzola, G., Angelucci, E., Marchese, Alessandra Maria, Pecile, P., Ventura, Giulio, Fanin, R., Scarparo, C., Barbaro, A., Leotta, Salvatore Nuccio, Marchese, A. E., Becchimanzi, C., Donnarumma, D., Tringali, S., Baldi, M. T., Scalone, R., Picardi, A., Arcese, W., Fontana, Cecilia Alejandra, Giammarco, S., Spanu, Teresa, Crocchiolo, R., Casari, E., Mussetti, A., Conte, Eliana, Ensoli, F., Miragliotta, G., Marone, P., Arghittu, M., Greco, R., Forcina, A., Chichero, P., Di Bartolomeo, P., Fazii, P., Kroumova, V., Decembrino, N., Zecca, M., Pisapia, Giovanni, Palazzo, G., Lanino, E., Faraci, M., Castagnola, E., Bandettini, R., Pastano, R., Sammassimo, S., Passerini, R., Stefani, P. M., Gherlinzoni, F., Rigoli, R., Prezioso, L., Cambo, B., Calderaro, A., Carella, A. M., Cascavilla, N., Labonia, M. T., Celeghini, I., Mordini, N., Piana, F., Vacca, A., Sanna, Maria Maddalena, Podda, G., Corsetti, M. T., Rocchetti, A., Cilloni, D., De Gobbi, M., Bianco, O., Fagioli, F., Carraro, F., De Intinis, G., Severino, A., Proia, Anna Silvia, Parisi, G., Vallisa, D., Confalonieri, Marco, Russo, D., Malagola, M., Galieni, P., Falcioni, S., Travaglini, V., Raimondi, Maria Rosa, Borghero, C., Pavan, Giuseppe, Prete, A., Belotti, T., Ambretti, S., Imola, M., Mianulli, A. M., Pedna, M. F., Cesaro, S., Lo Cascio, G., Ferrari, A., Piedimonte, M., Santino, I., Calandrelli, M., Olivieri, Alessandra, Orecchioni, F., Mirabile, M., Centurioni, R., Gironacci, L., Caravelli, D., Gallo, S., De Filippi, M., Cupelli, L., Dentamaro, T., Falco, S., Eugenio, O. S., Marotta, S., Risitano, A., Lula, D., Musto, P., Pietrantuono, G., Traficante, A., Cerchiara, E., Tirindelli, M. C., Dicuonzo, G., Chierichini, A., Anaclerico, B., Placanica, P., Sica S. (ORCID:0000-0003-2426-3465), Castagna L., Bruno B., Marchese A., Ventura G. (ORCID:0000-0002-0304-7264), Leotta S., Fontana C., Spanu T. (ORCID:0000-0003-1864-5184), Conte E., Pisapia G., Sanna M., Proia A., Confalonieri M. (ORCID:0000-0002-3708-379X), Raimondi R., Pavan G., Olivieri A., Girmenia, C., Bertaina, A., Piciocchi, A., Perruccio, K., Algarotti, A., Busca, A., Cattaneo, C., Raiola, A. M., Guidi, S., Iori, A. P., Candoni, A., Irrera, G., Milone, G., Marcacci, G., Scime, R., Musso, M., Cudillo, L., Sica, Simona, Castagna, Luigi, Corradini, P., Marchesi, F., Pastore, D., Alessandrino, E. P., Annaloro, C., Ciceri, F., Santarone, S., Nassi, L., Farina, C., Viscoli, C., Rossolini, G. M., Bonifazi, F., Rambaldi, A., Capria, S., Mastronuzzi, A., Pagliara, D., Bernaschi, P., Amico, L., Carotti, A., Mencacci, A., Bruno, Brunella, Costa, C., Passi, A., Ravizzola, G., Angelucci, E., Marchese, Alessandra Maria, Pecile, P., Ventura, Giulio, Fanin, R., Scarparo, C., Barbaro, A., Leotta, Salvatore Nuccio, Marchese, A. E., Becchimanzi, C., Donnarumma, D., Tringali, S., Baldi, M. T., Scalone, R., Picardi, A., Arcese, W., Fontana, Cecilia Alejandra, Giammarco, S., Spanu, Teresa, Crocchiolo, R., Casari, E., Mussetti, A., Conte, Eliana, Ensoli, F., Miragliotta, G., Marone, P., Arghittu, M., Greco, R., Forcina, A., Chichero, P., Di Bartolomeo, P., Fazii, P., Kroumova, V., Decembrino, N., Zecca, M., Pisapia, Giovanni, Palazzo, G., Lanino, E., Faraci, M., Castagnola, E., Bandettini, R., Pastano, R., Sammassimo, S., Passerini, R., Stefani, P. M., Gherlinzoni, F., Rigoli, R., Prezioso, L., Cambo, B., Calderaro, A., Carella, A. M., Cascavilla, N., Labonia, M. T., Celeghini, I., Mordini, N., Piana, F., Vacca, A., Sanna, Maria Maddalena, Podda, G., Corsetti, M. T., Rocchetti, A., Cilloni, D., De Gobbi, M., Bianco, O., Fagioli, F., Carraro, F., De Intinis, G., Severino, A., Proia, Anna Silvia, Parisi, G., Vallisa, D., Confalonieri, Marco, Russo, D., Malagola, M., Galieni, P., Falcioni, S., Travaglini, V., Raimondi, Maria Rosa, Borghero, C., Pavan, Giuseppe, Prete, A., Belotti, T., Ambretti, S., Imola, M., Mianulli, A. M., Pedna, M. F., Cesaro, S., Lo Cascio, G., Ferrari, A., Piedimonte, M., Santino, I., Calandrelli, M., Olivieri, Alessandra, Orecchioni, F., Mirabile, M., Centurioni, R., Gironacci, L., Caravelli, D., Gallo, S., De Filippi, M., Cupelli, L., Dentamaro, T., Falco, S., Eugenio, O. S., Marotta, S., Risitano, A., Lula, D., Musto, P., Pietrantuono, G., Traficante, A., Cerchiara, E., Tirindelli, M. C., Dicuonzo, G., Chierichini, A., Anaclerico, B., Placanica, P., Sica S. (ORCID:0000-0003-2426-3465), Castagna L., Bruno B., Marchese A., Ventura G. (ORCID:0000-0002-0304-7264), Leotta S., Fontana C., Spanu T. (ORCID:0000-0003-1864-5184), Conte E., Pisapia G., Sanna M., Proia A., Confalonieri M. (ORCID:0000-0002-3708-379X), Raimondi R., Pavan G., and Olivieri A.

Abstract

Background Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advisable. Methods We prospectively evaluated the epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods. we identified risk factors for GNB and evaluated the impact of GNB on the 4-month overall-survival after transplant. Results The cumulative incidence of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HSCT. Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were the most common isolates. By multivariate analysis, variables associated with GNB were a diagnosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and duration of severe neutropenia in allo-HSCT, and a diagnosis of lymphoma, older age, and no antibacterial prophylaxis in auto-HSCT. A pretransplant infection by a resistant pathogen was significantly associated with an increased risk of posttransplant infection by the same microorganism in allo-HSCT. Colonization by resistant gram-negative bacteria was significantly associated with an increased rate of infection by the same pathogen in both transplant procedures. GNB was independently associated with increased mortality at 4 months both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45-3.13; P <.001) and auto-HSCT (2.43; 1.22-4.84; P =.01). Conclusions Pre-engraftment GNB is an independent factor associated with increased mortality rate at 4 months after auto-HSCT and allo-HSCT. Previous infectious history and colonization monitoring represent major indicators of GNB. Clinical Trials registration NCT02088840.

Published
2017

55. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry

Author

Melillo, L., Tieghi, A., Candoni, A., Radaelli, F., Ciancia, R., Specchia, G., Martino, B., Scalzulli, P. R., Latagliata, R., Palmieri, F., Usala, E., Valente, D., Valvano, M. R., Cedrone, M., Comitini, G., Martinelli, V., Cascavilla, N., Gugliotta, L., Fanin, R., Iurlo, A., Zanella, A., Rotoli, B., Carluccio, P., Liso, V., Nobile, F., Santoro, C., Mazzucconi, M. G., Cantore, N., Angelucci, E., Annino, L., Cacciola, E., Cacciola, R., Giustolisi, R., Fanci, R., Bosi, A., Frungillo, N., Corradini, P., Patriarca, A., Dragani, A., De Muro, M., and Avvisati, G.

Subjects
Adult, Pediatrics, medicine.medical_specialty, Multivariate analysis, Adolescent, Alpha interferon, Abortion, Young Adult, Pregnancy, medicine, Humans, Registries, Retrospective Studies, Aspirin, Platelet Count, business.industry, Essential thrombocythemia, Obstetrics, Pregnancy Outcome, Retrospective cohort study, Hematology, Janus Kinase 2, Middle Aged, medicine.disease, Recombinant Proteins, Pregnancy Complications, Parity, Italy, Interferon Type I, Multivariate Analysis, Mutation, Gestation, Female, business, Live birth, Thrombocythemia, Essential
Abstract

Pregnancy is a high-risk event in women with essential thrombocythemia (ET). This observational study evaluated pregnancy outcome in ET patients focusing on the potential impact of aspirin (ASA) or interferon alpha (IFN) treatment during pregnancy. We retrospectively analyzed 122 pregnancies in 92 women consecutively observed in the last 10 years in 17 centers of the Italian thrombocythemia registry (RIT). The live birth rate was 75.4% (92/122 pregnancies). The risk of spontaneous abortion was 2.5-fold higher than in the control population (P < 0.01). ASA did not affect the live birth rate (71/93, 76.3% vs. 21/29, 72.4%, P = 0.67). However, IFN treatment during pregnancy was associated with a better outcome than was management without IFN (live births 19/20, 95% vs. 73/102, 71.6%, P = 0.025), and this finding was supported by multivariate analysis (OR: 0.10; 95% CI: 0.013-0.846, P = 0.034). The JAK2 V617F mutation was associated with a poorer outcome (fetal losses JAK2 V617F positive 9/25, 36% vs. wild type 2/24, 8.3%, P = 0.037), and this association was still significant after multivariate analysis (OR: 6.19; 95% CI: 1.17-32.61; P = 0.038). No outcome concordance between first and second pregnancies was found (P = 0.30). Maternal complications occurred in 8% of cases. In this retrospective study, in consecutively observed pregnant ET patients, IFN treatment was associated with a higher live birth rate, while ASA treatment was not. In addition, the JAK2 V617F mutation was confirmed to be an adverse prognostic factor.

Published
2009

56. LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY

Author

Luminari, S., primary, Tarantino, V., additional, Anastasia, A., additional, Boccomini, C., additional, Chiarenza, A., additional, Rigacci, L., additional, Angelucci, E., additional, Ferrari, A., additional, Pulsoni, A., additional, Rattotti, S., additional, Angrilli, F., additional, Gaidano, G., additional, Stelitano, C., additional, Bertoldero, G., additional, Cascavilla, N., additional, Salvi, F., additional, Ferreri, A.J., additional, Vallisa, D., additional, Balzarotti, M., additional, Cox, M.C., additional, Freilone, R., additional, Marcheselli, L., additional, Dondi, A., additional, Manni, M., additional, and Federico, M., additional

Published
2017
Full Text
View/download PDF

57. POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL.

Author

Luminari, S., primary, Marcheselli, L., additional, Manni, M., additional, Anastasia, A., additional, Vitolo, U., additional, Chiarenza, A., additional, Rigacci, L., additional, Angelucci, E., additional, Fama, A., additional, Pulsoni, A., additional, Rattotti, S., additional, Angrilli, F., additional, Gaidano, G., additional, Stelitano, C., additional, Bertoldero, G., additional, Cascavilla, N., additional, Salvi, F., additional, Ferreri, A.J., additional, Tarantino, V., additional, Bellei, M., additional, and Federico, M., additional

Published
2017
Full Text
View/download PDF

58. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Author

Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, Quartarone E., Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, and Quartarone E.

Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Published
2012

59. Cardiovascular events and intensity of treatment in polycythemia vera

Author

Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, De Stefano, V, Elli, E, Iurlo, A, Latagliata, R, Lunghi, F, Lunghi, M, Marfisi, Rm, Musto, P, Masciulli, A, Musolino, C, Cascavilla, N, Quarta, G, Randi, M. L., Rapezzi, D, Ruggeri, M, Rumi, E, Scortechini, Ar, Santini, S, Scarano, M, Siragusa, S, Spadea, A, Tieghi, A, Angelucci, E, Visani, G, Vannucchi, Am, Specchia G, Barbui T., D'Amico, A, Ferri, B, Guido, C, Marfisi, L, Pera, C, Polidoro, A, Sacco, M, Levantesi, G, Tognoni, G, Barosi, G, Carobbio, A, Leoni, P, Mulattieri, S, Tomassetti, S, Honorati, E, Ricco, A, Albano, F, Pastore, D, Carluccio, P, Mazzone, Am, Rossi, Ar, Finazzi, Mc, Delaini, F, Falanga, A, Rambaldi, A, Guaragna, G, Giannotta, A, Usala, E, Simula, Mp, Pilo, F, Cacciola, E, Pezzella, F, Seria, E, Di Francesco, E, Gallamini, A, Bertolotti, L, Antonioli, E, Guglielmelli, P, Pieri, L, Susini, Mc, Bartalucci, N, Bosi, A, D'Angelo, A, Centorrino, R, Gerace, D, Allegra, A, Cortelezzi, A, De Philippis, C, Ferretti, E, Ciceri, F, Claudiani, S, Malato, S, Trinca, S, Pogliani, Em, Belotti, A, Lanzi, E, Elli, Em, Gaidano, G, Deambrogi, C, Rossi, D, Saglio, G, Rotolo, A, Zanone, C, Bertozzi, I, Tezza, F, Aneloni, V, Quintini, G, Saccullo, G, Caracciolo, C, Cazzola, M, Casetti, I, Elena, C, Landini, B, Barulli, S, Guiducci, B, Lucesole, M, Malerba, L, Isidori, A, Grossi, A, De Stefanis, M, Biagioni, C, Merli, F, Imovilli, A, Codeluppi, K, Rubagotti, S, Romano, N, Bonini, A, Bellesia, E, Martorelli, Mc, Villani, O, Zifarone, E, Zonno, A, Santopietro, V, Za, T, Rossi, E, Ciminello, Am, Betti, S, Alimena, G, Tafuri, A, Breccia, M, Carmosino, I, Pisani, F, Romano, A, D'Andrea, M, Nobile, M, Mantuano, Fs, Rossi, G, Tricarico, M, Rodeghiero, F, Bedin, F, Lissandrini, L, Finotto, S., Marchioli, R, Finazzi, G, Specchia, G, Cacciola, R, Cavazzina, R, Cilloni, D, De Stefano, V, Elli, E, Iurlo, A, Latagliata, R, Lunghi, F, Lunghi, M, Marfisi, RM, Musto, P, Masciulli, A, Musolino, C, Cascavilla, N, Quarta, G, Randi, ML, Rapezzi, D, Ruggeri, M, Rumi, E, Scortechini, AR, Santini, S, Scarano, M, Siragusa, S, Spadea, A, Tieghi, A, Angelucci, E, Visani, G, Vannucchi, AM, Barbui, T, and CYTO-PV Collaborative Group.

Subjects
Male, Hematocrit, RECURRENT THROMBOSIS, law.invention, Aged, Antineoplastic Agents, Cardiovascular Diseases, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Hydroxyurea, Janus Kinase 2, Middle Aged, Polycythemia Vera, Thrombosis, Phlebotomy, Medicine (all), LEUKOCYTOSIS, Polycythemia vera, Randomized controlled trial, law, hemic and lymphatic diseases, ESSENTIAL THROMBOCYTHEMIA, Clinical endpoint, Polycythemia Vera, Secondary Prophylaxis, ESSENTIAL THROMBOCYTHEMIA, RECURRENT THROMBOSIS, RISK-FACTOR, HEMATOCRIT, MANAGEMENT, LEUKOCYTOSIS, PREVENTION, DIAGNOSIS, EFFICACY, WARFARIN, medicine.diagnostic_test, Hazard ratio, General Medicine, medicine.medical_specialty, randomized trial, polycythemia vera, Cardiovascular event, DIAGNOSIS, WARFARIN, RISK-FACTOR, Internal medicine, MANAGEMENT, medicine, Myelofibrosis, Adverse effect, business.industry, EFFICACY, medicine.disease, PREVENTION, Surgery, Polycythemia Vera, Cardiovascular event, hematocrit, Settore MED/15 - MALATTIE DEL SANGUE, business
Abstract

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit

Published
2013

60. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)

Author

Caira, M., Candoni, A., Verga, L., Busca, A., Delia, M., Nosari, A., Caramatti, C., Castagnola, C., Cattaneo, C., Fanci, R., Chierichini, A., Melillo, L., Mitra, M. E., Picardi, M., Potenza, L., Salutari, P., Vianelli, N., Facchini, L., Cesarini, M., De Paolis, M. R., Di Blasi, R., Farina, F., Venditti, A., Ferrari, A., Garzia, M., Gasbarrino, C., Invernizzi, R., Lessi, F., Manna, A., Martino, B., Nadali, G., Offidani, M., Paris, L., Pavone, V., Rossi, G., Spadea, A., Specchia, G., Trecarichi, E. M., Vacca, A., Cesaro, S., Perriello, V., Aversa, F., Tumbarello, M., Pagano, L., Ragionieri, R., Orsola Malpighi, O. S., Antoniazzi, F., Storti, S., Luppi, M., Pagliuca, S., Rossetti, E., Da Vià, M., Di Caprio, L., Majolino, I., Cascavilla, N., Turri, G., Fanin, Renato, Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne, Caira, Morena, Candoni, Anna, Verga, Luisa, Busca, Alessandro, Delia, Mario, Nosari, Annamaria, Caramatti, Cecilia, Castagnola, Carlo, Cattaneo, Chiara, Fanci, Rosa, Chierichini, Anna, Melillo, Lorella, Mitra, Maria Enza, Picardi, Marco, Potenza, Leonardo, Salutari, Prassede, Vianelli, Nicola, Facchini, Luca, Cesarini, Monica, De Paolis, Maria Rosaria, Di Blasi, Roberta, Farina, Francesca, Venditti, Adriano, Ferrari, Antonella, Garzia, Mariagrazia, Gasbarrino, Cristina, Invernizzi, Rosangela, Lessi, Federica, Manna, Annunziata, Martino, Bruno, Nadali, Gianpaolo, Offidani, Massimo, Paris, Laura, Pavone, Vincenzo, Rossi, Giuseppe, Spadea, Antonio, Specchia, Giorgina, Trecarichi, Enrico Maria, Vacca, Adriana, Cesaro, Simone, Perriello, Vincenzo, Aversa, Franco, Tumbarello, Mario, and Pagano, Livio

Subjects
Myeloid, Male, Antifungal Agents, invasive fungal diseases, Mycose, Risk Factors, Epidemiology, Antineoplastic Combined Chemotherapy Protocols, Antifungal Agent, Prospective Studies, Prospective cohort study, Univariate analysis, leukemia, Myeloid leukemia, Hematology, Environmental exposure, Articles, Middle Aged, Prognosis, Survival Rate, Leukemia, Leukemia, Myeloid, Acute, Female, Case-Control Studie, Human, Adult, medicine.medical_specialty, Prognosi, risk factors, acute myeloid leukemia, Neutropenia, Acute, Settore MED/17 - MALATTIE INFETTIVE, Aged, Case-Control Studies, Follow-Up Studies, Humans, Mycoses, Neoplasm Staging, Immunocompromised Host, Follow-Up Studie, Internal medicine, medicine, Antineoplastic Combined Chemotherapy Protocol, Performance status, business.industry, Risk Factor, medicine.disease, Surgery, Prospective Studie, Settore MED/15 - MALATTIE DEL SANGUE, Fungal Disease, business
Abstract

Correct definition of the level of risk of invasive fungal infections is the first step in improving the targeting of preventive strategies. We investigated the potential relationship between pre-hospitalization exposure to sources of fungi and the development of invasive fungal infections in adult patients with newly diagnosed acute myeloid leukemia after their first course of chemotherapy. From January 2010 to April 2012, all consecutive acute myeloid leukemia patients in 33 Italian centers were prospectively registered. Upon first admission, information about possible pre-chemotherapy risk factors and environmental exposure was collected. We recorded data regarding comorbid conditions, employment, hygienic habits, working and living environment, personal habits, hobbies, and pets. All invasive fungal infections occurring within 30 days after the first course of chemotherapy were recorded. Of the 1,192 patients enrolled in this study, 881 received intensive chemotherapy and were included in the present analysis. Of these, 214 developed an invasive fungal infection, including 77 proven/probable cases (8.7%). Of these 77 cases, 54 were proven/probable invasive mold infections (6.1%) and 23 were proven yeast infections (2.6%). Upon univariate analysis, a significant association was found between invasive mold infections and age, performance status, diabetes, chronic obstructive pulmonary disease, smoking, cocaine use, job, hobbies, and a recent house renovation. Higher body weight resulted in a reduced risk of invasive mold infections. Multivariate analysis confirmed the role of performance status, job, body weight, chronic obstructive pulmonary disease, and house renovation. In conclusion, several hospital-independent variables could potentially influence the onset of invasive mold infections in patients with acute myeloid leukemia. Investigation of these factors upon first admission may help to define a patient's risk category and improve targeted prophylactic strategies. (Clinicaltrial.gov: NCT01315925)

Published
2015

61. Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification

Author

Chiaretti, S, Vitale, A, Elia, L, Fedullo, Al, Albino, S, Piciocchi, A, Fazi, P, DI RAIMONDO, Francesco, Fornaro, A, Fabbiano, F, D'Arco, Am, Martinelli, G, Ronco, F, Santoro, Le, Cascavilla, N, Galieni, P, Tedeschi, A, Sica, S, Di Renzo, N, Melpignano, A, Carella, Am, Ferrara, F, Vignetti, M, and Foa, R.

Published
2015

62. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma

Author

Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio COLLABORATORI: Tosi, P, Motta, Mr, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, Franco, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, Mc, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, Am, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, Mc, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E., Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A., Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio, Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, and Quartarone, E

Subjects
Male, Boronic Acid, medicine.medical_treatment, PLUS DEXAMETHASONE, Phases of clinical research, Kaplan-Meier Estimate, Hematopoietic stem cell transplantation, Biochemistry, Antineoplastic Agent, Bortezomib-thalidomide-dexamethasone, Bortezomib, Immunosuppressive Agent, Autologous stem-cell transplantation, MULTIPLE MYELOMA, Antineoplastic Combined Chemotherapy Protocols, thalidomide-dexamethasone, Multiple myeloma, RANDOMIZED PHASE-3, LENALIDOMIDE, STEM CELL TRANSPLANTATION, Hematopoietic Stem Cell Transplantation, PHASE-III TRIAL, Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, Boronic Acids, Combined Modality Therapy, Thalidomide, Transplantation, Autologou, Pyrazines, HIGH-DOSE MELPHALAN, INDUCTION TREATMENT, Female, Autologous, Immunosuppressive Agents, Pyrazine, Human, medicine.drug, MAINTENANCE THERAPY, medicine.medical_specialty, DOXORUBICIN, Antineoplastic Agents, Hormonal, Prognosi, Immunology, Urology, Antineoplastic Agents, dexamethasone, Transplantation, Autologous, Disease-Free Survival, Dexamethasone, Humans, Multiple Myeloma, Cell Biology, medicine, Autologous transplantation, METAANALYSIS, Transplantation, Antineoplastic Combined Chemotherapy Protocol, Hormonal, business.industry, medicine.disease, Surgery, business, Settore MED/15 - Malattie del Sangue
Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Published
2012

63. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

Author

Morabito, F, Gentile, M, Mazzone, C, Rossi, D, Di Raimondo, F, Bringhen, S, Ria, R, Offidani, M, Patriarca, F, Nozzoli, C, Petrucci, Mt, Benevolo, G, Vincelli, I, Guglielmelli, T, Grasso, M, Marasca, R, Baldini, L, Montefusco, V, Musto, P, Cascavilla, N, Majolino, I, Musolino, Caterina, Cavo, M, Boccadoro, M, Palumbo, A, Musolino, C., Morabito F., Gentile M., Mazzone C., Rossi D., Di Raimondo F., Bringhen S., Ria R., Offidani M., Patriarca F., Nozzoli C., Petrucci M.T., Benevolo G., Vincelli I., Guglielmelli T., Grasso M., Marasca R., Baldini L., Montefusco V., Musto P., Cascavilla N., Majolino I., Musolino C., Cavo M., Boccadoro M., and Palumbo A.

Subjects
Melphalan, Male, CHRONIC KIDNEY-DISEASE, DOXORUBICIN-DEXAMETHASONE BDD, PRESENTING FEATURES, FAILURE ARF, PHASE-II, REGIMENS, REVERSIBILITY, PATHOGENESIS, REVERSAL, SURVIVAL, Biochemistry, Bortezomib, chemistry.chemical_compound, MULTIPLE MYELOMA, Prednisone, Multiple myeloma, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma, thalidomide, bortezomib-melphalan-prednisone, Kidney, treatment, Hematology, Induction Chemotherapy, Boronic Acids, Neoadjuvant Therapy, Thalidomide, medicine.anatomical_structure, Treatment Outcome, Pyrazines, Female, Kidney Diseases, medicine.drug, Glomerular Filtration Rate, renal impairment, medicine.medical_specialty, Immunology, Urology, Renal function, MPT-VT, Maintenance Chemotherapy, medicine, Humans, Adverse effect, Aged, Creatinine, business.industry, Cell Biology, medicine.disease, Survival Analysis, Surgery, melphalan, chemistry, VMP, prednisone, bortezomib-melphalan-prednisone-thalidomide, business
Abstract

We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednisone (VMP). Exclusion criteria included serum creatinine ≥ 2.5 mg/dL. In the VMPT-VT/VMP arms, severe RI (estimated glomerular filtration rate [eGFR] ≤ 30 mL/min), moderate RI (eGFR 31-50 mL/min), and normal renal function (eGFR > 50 mL/min), were 6%/7.9%, 24.1%/24.9%, and 69.8%/67.2%, respectively. Statistically significant improvements in overall response rates and progression-free survival were observed in VMPT-VT versus VMP arms across renal cohorts, except in severe RI patients. In the VMPT group, severe RI reduced overall survival (OS). RI was reversed in 16/63 (25.4%) patients receiving VMPT-VT versus 31/77 (40.3%) receiving VMP. Multivariate analysis showed male sex (P = .022) and moderate RI (P = .003) significantly predicted RI recovery. VMP patients achieving renal response showed longer OS. In both arms, greater rates of severe hematologic adverse events were associated with RI (eGFR < 50 mL/min), however, therapy discontinuation rates were unaffected. VMPT-VT was superior to VMP for cases with normal renal function and moderate RI, whereas VMPT-VT failed to outperform VMP in patients with severe RI, although the relatively low number of cases analyzed preclude drawing definitive conclusions. VMPT-VT had no advantage in terms of RI reversal over VMP. This study is registered at http://www.clinicaltrials.gov as NCT01063179.

Published
2011

64. Chronic myeloid leukemia as second malignancy; restrospective multicentric study

Author

Iannitto, E, Minardi, V, Barone, R, Cascavilla, N, Caracciolo, C, Di Raimondo, F, Ferrara, F, FRANCO, Giovanni, Liardo, E, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmieri, F, Russo Rossi, A, Specchia, G, Turri, D, Abbadessa, V., MANCUSO, Salvatrice, Iannitto, E, Minardi, V, Barone, R, Cascavilla, N, Caracciolo, C, Di Raimondo, F, Ferrara, F, Franco, G, Liardo, E, Mancuso, S, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmieri, F, Russo Rossi, A, Specchia, G, Turri, D, and Abbadessa, V

Subjects
chronic myeloid leukemia, second malignancy, Settore MED/15 - Malattie Del Sangue
Published
2009

65. Chronic myeloid leukemia as second malignancy; a retrospective multicentrico study

Author

Iannitto, E, Minardi, V, Barone, R, Cascavilla, N, Caracciolo, C, Di Raiomondo, F, Ferrara, F, FRANCO, Giovanni, Liardo, E, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmieri, F, Russo Rossi, A, Specchia, G, Turri, D, Abbadessa, V., MANCUSO, Salvatrice, Iannitto, E, Minardi, V, Barone, R, Cascavilla, N, Caracciolo, C, Di Raiomondo, F, Ferrara, F, Franco, G, Liardo, E, Mancuso, S, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmieri, F, Russo Rossi, A, Specchia, G, Turri, D, and Abbadessa, V

Subjects
chronic myeloid leukemia, secondary malignancy, Settore MED/15 - Malattie Del Sangue
Published
2009

66. Allotransplant after autologous haematopoietic stem cell transplantation relapse in aggressive lymphoma patients: update af a retrospective GITMO study

Author

Rigacci L, Bosi A, Puccini B, Corradini P, Castagna L, Cascavilla N, Milone G, Bacigalupo A, Scime R, Specchia G, Rambaldi A, Leoni P, Levis A, Guidi S, Bruno B, Oneto R, Fanin R., CICERI , FABIO, Rigacci, L, Bosi, A, Puccini, B, Corradini, P, Castagna, L, Cascavilla, N, Milone, G, Bacigalupo, A, Scime, R, Specchia, G, Rambaldi, A, Leoni, P, Ciceri, Fabio, Levis, A, Guidi, S, Bruno, B, Oneto, R, and Fanin, R.

Published
2009

67. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma

Author

Lanza, F., Lemoli, R. M., Olivieri, A., Laszlo, D., Martino, M., Specchia, G., Pavone, V., Imola, M., Pasini, A., Milone, G., Scortechini, I., Todisco, E., Guggiari, E., Cascavilla, N., Martinelli, G., Rambaldi, A., and Bosi, A.

Subjects
Adult, Male, Benzylamines, Receptors, CXCR4, Adolescent, Lymphoma, Cyclams, NO, Aged, Blood Component Removal, Chemoradiotherapy, Data Collection, Female, Hematopoietic Stem Cell Mobilization, Heterocyclic Compounds, Humans, Italy, Leukapheresis, Middle Aged, Multiple Myeloma, Platelet Count, Predictive Value of Tests, Prospective Studies, Young Adult, Receptors, CXCR4
Abstract

Although the efficacy of plerixafor in peripheral blood stem cell (PBSC) mobilization has been explored in several studies, factors associated with successful plerixafor mobilization after administration of granulocyte-colony-stimulating factor (G-CSF), with or without chemotherapy, have not been investigated. We analyzed data on PBSC mobilization from a large Italian database of lymphoma and myeloma plerixafor-treated patients.Two endpoints were established to define successful mobilization: patients with at least 2 × 10(6) CD34+ cells/kg collected by three leukapheresis procedures and patients achieving a peak count of at least 20 × 10(6) CD34+ cells/L during mobilization.Plerixafor achieved successful mobilization in both predicted (n = 64) and proven poor mobilizers (PMs; n = 143), classified according to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) criteria. Successful mobilization was independent of type of mobilization (steady state or chemotherapy); age; sex; disease; number or type of chemotherapy regimens preceding plerixafor; radiation therapy; prior treatment with melphalan, carmustine, lenalidomide, and radioimmune conjugates; and laboratory variables. Multivariate analysis identified previous fludarabine treatment and premobilization platelet count as predictors of successful mobilization.This large, prospective, nationwide study confirmed plerixafor efficacy for mobilizing PBSCs when added to G-CSF with or without chemotherapy. Plerixafor can overcome negative effects of most predictors of poor mobilization to achieve satisfactory harvest both in predicted and proven PM.

Published
2014

68. Allotransplant as salvage therapy after autologous haematopoietic stem cell transplantation relapse in diffuse large B cell lymphoma patients: a retrospective GITMO study

Author

Rigacci L, Bosi A, Puccini B, Corradini P, Castagna L, Cascavilla N, Milone G, Bacigalupo A, ScimS R, Specchia G, Rambaldi A, Leoni P, Levis A, Guidi S, Bruno B, Fanin R., CICERI , FABIO, Rigacci, L, Bosi, A, Puccini, B, Corradini, P, Castagna, L, Cascavilla, N, Milone, G, Bacigalupo, A, Scims, R, Specchia, G, Rambaldi, A, Leoni, P, Ciceri, Fabio, Levis, A, Guidi, S, Bruno, B, and Fanin, R.

Published
2008

69. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

Author

Cascavilla, N, DE STEFANO, VALERIO, Pane, F, Pancrazzi, A, Iurlo, A, Gobbi, M, Palandri, F, Specchia, G, Liberati, AM, D'Adda, M, Gaidano, G, Fjerza, R, Achenbach, H, Smith, J, Wilde, P, Vannucchi, AM, Cascavilla, N, DE STEFANO, VALERIO, Pane, F, Pancrazzi, A, Iurlo, A, Gobbi, M, Palandri, F, Specchia, G, Liberati, AM, D'Adda, M, Gaidano, G, Fjerza, R, Achenbach, H, Smith, J, Wilde, P, and Vannucchi, AM

Published
2015

70. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients

Author

Zinzani, Pl, Vitolo, U, Viviani, S, Corradini, P, Motta, G, Tani, M, Cascavilla, N, Hohaus, Stefan, Merli, F, Argnani, L, Broccoli, A, Hohaus, S (ORCID:0000-0002-5534-7197), Zinzani, Pl, Vitolo, U, Viviani, S, Corradini, P, Motta, G, Tani, M, Cascavilla, N, Hohaus, Stefan, Merli, F, Argnani, L, Broccoli, A, and Hohaus, S (ORCID:0000-0002-5534-7197)

Abstract

The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation.

Published
2015

72. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Author

Alessandrino, Ep, Porta, Mg, Malcovati, L, Jackson, Ch, Pascutto, C, Bacigalupo, A, Teresa van Lint, M, Falda, M, Bernardi, M, Onida, F, Guidi, S, Iori, Ap, Cerretti, R, Marenco, P, Pioltelli, P, Angelucci, E, Oneto, R, Ripamonti, F, Rambaldi, A, Bosi, A, Cazzola, M, Gruppo Italiano Trapianto di Midollo Osseo Levis, A, Bandini, G, Casini, M, Rossi, G, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Van Lint MT, Corradini, P, Milani, R, Morra, E, Lambertenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scime, R, Iannitto, E, Musso, M, Locatelli, F, Zecca, M, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Merli, F, Foa, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Fanin, R, Cerno, M, Bortolo, S, and Author information, Raimondi R.

Subjects
Oncology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Cohort Studies, Female, Humans, Male, Markov Chains, Middle Aged, Myelodysplastic Syndromes, Risk, Survival Analysis, Time Factors, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Hematology, Homologous, medicine.medical_specialty, Allogeneic transplantation, medicine.medical_treatment, Hematopoietic stem cell transplantation, Natural history of disease, Internal medicine, medicine, 80 and over, Survival analysis, Transplantation, business.industry, Myelodysplastic syndromes, Original Articles, medicine.disease, Settore MED/15, Surgery, allogeneic transplantation, International Prognostic Scoring System, Risk assessment, business
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferior overall survival. To define the optimal timing of allogeneic HSCT, we carried out a decision analysis by studying 660 patients who received best supportive care and 449 subjects who underwent transplantation. Risk assessment was based on both the International Prognostic Scoring System (IPSS) and the World Health Organization classification-based Prognostic Scoring System (WPSS). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of allogeneic HSCT on survival. This model estimated life expectancy from diagnosis according to treatment policy at different risk stages. Relative to supportive care, estimated life expectancy increased when transplantation was delayed from the initial stages until progression to intermediate-1 IPSS-risk or to intermediate WPSS-risk stage, and then decreased for higher risks. Modeling decision analysis on WPSS versus IPSS allowed better estimation of the optimal timing of transplantation. These observations indicate that allogeneic HSCT offers optimal survival benefits when the procedure is performed before MDS patients progress to advanced disease stages. Am. J. Hematol. 88:581–588, 2013. © 2013 Wiley Periodicals, Inc.

Published
2013

73. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

Author

Tafuri, Agostino, Gregorj, C, Petrucci, Mt, Ricciardi, Maria Rosaria, Mancini, M, Cimino, Giuseppe, Mecucci, C, Tedeschi, A, Fioritoni, G, Ferrara, F, DI RAIMONDO, F, Gallo, E, Liso, V, Fabbiano, F, Cascavilla, N, Pizzolo, G, Camera, A, Pane, F, Lanza, F, Cilloni, D, Annino, L, Vitale, A, Vegna, Ml, Vignetti, Marco, Foa, Roberto, Mandelli, Franco, ON BEHALF OF THE GIMEMA GROUP, Tafuri, A., Gregorj, C., Petrucci, M. T., Ricciardi, M. R., Mancini, M., Cimino, G., Mecucci, C., Tedeschi, A., Fioritoni, G., Ferrara, F., DI RAIMONDO, F., Gallo, E., Liso, V., Fabbiano, F., Cascavilla, N., Pizzolo, G., Camera, A., Pane, Fabrizio, Lanza, F., Cilloni, D., Annino, L., Vitale, A., Vegna, M. L., Vignetti, M., Foa, R., and Mandelli, F.

Subjects
Male, medicine.medical_treatment, physiological processes, Biochemistry, Gastroenterology, Gene expression, polycyclic compounds, Prospective Studies, Prospective cohort study, P-glycoprotein, Univariate analysis, biology, GIMEMA ALL0496 protocol, adult, Remission Induction, Hematology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Flow Cytometry, Prognosis, Treatment Outcome, Female, multiple drug resistance (MDR1), multiple drug resistance (MDR1), protein expression, independent predictor of complete remission, adult, acute lymphoblastic leukemia,GIMEMA ALL0496 protocol, medicine.medical_specialty, Adolescent, Immunology, Bone Marrow Cells, Context (language use), acute lymphoblastic leukemia, NO, Acute lymphocytic leukemia, Internal medicine, medicine, Humans, ATP Binding Cassette Transporter, Subfamily B, Member 1, neoplasms, protein expression, Analysis of Variance, Chemotherapy, Blood Cells, business.industry, independent predictor of complete remission, Cell Biology, medicine.disease, biology.protein, Adult Acute Lymphoblastic Leukemia, Blast Crisis, business, ACUTE MYELOID-LEUKEMIA, P-GLYCOPROTEIN EXPRESSION, MULTIDRUG-RESISTANCE MDR1, Biomarkers
Abstract

Little is known about the prognostic role of multidrug resistance (MDR) in adults with newly diagnosed acute lymphoblastic leukemia (ALL). In the context of the GIMEMA ALL0496 protocol, we evaluated the impact of MDR1 (protein expression and function) on the achievement of complete remission (CR) and clinical outcome. Flow cytometric analysis of MDR1 expression (D) and function (rhodamine-123 efflux) was obtained in 203 and 158 patients, respectively. MDR1 expression was detected in 44 (21.7%) of 203 patients, and function was found in 23 (14.6%) of 158 (14.6%) patients. Expression of the multidrug resistance-associated protein 1 (MRP1) and lung-resistance protein (LRP) evaluated in 43 samples was found in 13 and 26 patients, respectively. Among the 200 patients evaluable for the clinical correlation study, 125 (79.6%) of 157 without MDR1 expression achieved CR compared with 23 (53.5%) of 43 with MDR1 expression (P =.001). At univariate analysis, MDR1 expression was significantly associated with CR when considered as a dichotomized (P =.001) or continuous (P =.01) variable. At multivariate analysis, dichotomized evaluation of MDR1 expression independently predicted CR (P =.004) with age (P =.03) and CD34 (P =.03); as a continuous variable, MDR1 expression (P =.03) was the only significant factor other than CD34 (P =.01). MDR1 function failed to predict achievement of CR or of MRP1 and LRP expression. MDR1 expression did not correlate with CR duration, nor did it predict for survival duration. These results demonstrate that MDR1 expression in de novo adult ALL is an independent predictor of CR achievement.

Published
2002

74. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

Author

Cortelezzi, A, Gritti, G, Laurenti, L, Cuneo, Antonio, Ciolli, S, Di Renzo, N, Musto, P, Mauro, Fr, Cascavilla, N, Falchi, L, Zallio, F, Callea, V, Maura, F, Martinelli, S, Piciocchi, A, Reda, G, Foà, R, and on behalf of the GIMEMA Chronic Lymphoproliferative Disorders Working Party

Subjects
Chronic lymphocytic leukaemia, Alemtuzumab, Infection, Monoclonal antibodies
Published
2012

75. Cytoreductive combination therapy in essential trhombocythemia: preliminary report of the Registro Italiano trombocitemia (RIT)

Author

Gugliotta, L, Scalzulli, P, Tighi, A, Codeluppi, K, Valvano, R, Candoni, A, Chiozzotto, E, Liberati, M, Apolloni, V, Specchia, G, Cacciola, Emma, Cacciola, Rossella Rosaria, Mastrullo, R, Villa, M, Prugnola, M, Martinelli, V, Ciancia, R, Mazzucconi, Mg, Santoro, C, Campana, P, Randi, Ml, De Biasi, E, Maschio, N, Lanza, F, Antonioli, E, Pierri, I, Di Ianni, M, Iurlo, A, Piccin, A, and Cascavilla, N.

Published
2012

76. A SINGLE-ARM MULTI-CENTER TRIAL OF BENDAMUSTINE GIVEN WITH OFATUMUMAB (BENDOFA) IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA. GIMEMA CLL0809 PROTOCOL

Author

Cortelezzi, A., Liberati, Am, Sciume, M., Cuneo, A., Reda, G., Gritti, G., Laurenti, L., Zaja, F., Marasca, R., Chiarenza, A., Orsucci, L., Storti, S., Murru, R., Cascavilla, N., Gobbi, M., Mauro, Francesca Romana, Gregorini, A., Morabito, F., Fabris, S., Maura, F., Piciocchi, A., Vignetti, M., Neri, A., Rossi, D., Gaidano, G., Marinelli, M., Guarini, Anna, and Foa, Roberto

Published
2012

77. THROMBOPROPHYLAXIS FOR NEWLY DIAGNOSED MULTIPLEMYELOMA PATIENTS TREATED WITH LENALIDOMIDE-BASEDREGIMENS: A RANDOMIZED PHASE III STUDY OF ASPIRINVS ENOXAPARIN

Author

Larocca, Alessandra, Cavallo, Federica, Evangelista, A., Di Raimondo, F., Catalano, L., Galli, M., Cangialosi, C., Benevolo, G., Rossi, D., Guglielmelli, T., Masini, L., Rossi, F., Ria, R., Cascavilla, N., Pescosta, N., Baraldi, A., Marcatti, M., Caravita Di Toritto, T., Nagler, A., Boccadoro, Mario, and Palumbo, Antonio

Published
2011

79. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients

Author

D'Arena, G, Capalbo, S, Laurenti, L, Del Poeta, G, Nunziata, G, Deaglio, Silvia, Spinosa, G, Tarnani, M, Di Padua, L, Califano, C, Ferrara, F, and Cascavilla, N.

Subjects
Male, Murine-Derived, Disease-Free Survival, Antibodies, Antibodies, Monoclonal, Murine-Derived, Monoclonal, 80 and over, Immunologic Factors, Humans, Retrospective Studies, Aged, Survival Rate, Aged, 80 and over, Leukemia, Lymphocytic, Chronic, B-Cell, Purpura, Thrombocytopenic, Idiopathic, Follow-Up Studies, Middle Aged, Female, Remission Induction, Chronic, Purpura, immune thrombocytopenia, chronic lymphocytic leukemia, rituximab, Leukemia, B-Cell, Idiopathic, Lymphocytic, Thrombocytopenic, Rituximab, Settore MED/15 - Malattie del Sangue
Abstract

There are no standard therapies for chronic lymphocytic leukemia (CLL)-associated immune thrombocytopenia (IT) so far.We report the results of therapy with single agent rituximab in 21 patients with CLL-associated IT. The mean age at CLL and IT diagnosis was 64 and 68 yr, respectively. IT developed at a mean time of 44 months from the diagnosis of CLL. In four cases, IT was diagnosed at the same time as CLL. For three patients, IT was considered fludarabine-related and two patients showed autoimmune hemolysis also. All patients but one received steroids as first-line treatment for IT. Some patients received intravenous high-dose Ig, vincristine, and Cytoxan also, without beneficial effect. After a mean time of 43 d from the diagnosis of IT, all patients were scheduled to receive rituximab at a dosage of 375 mg/mq/weekly.Eighteen (86%) patients completed the scheduled four cycles of rituximab. Irrelevant first infusion side effects were seen only in one patient. Twelve (57%) patients showed a complete response (CR), six (29%) patients a partial response (PR), and three (14%) patients did not respond. In responding patients, the mean duration of response was 21 months (4-49 months). At a mean follow-up of 28 months, 14 (66%) patients were still alive, 10 (48%) of them in CR and three (14%) in PR.This retrospective analysis prove that rituximab is an effective and well-tolerated alternative treatment for CLL-associated IT.

Published
2010

80. Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients

Author

Cerrato, C., primary, Gay, F., additional, Petrucci, M.T., additional, Pellegrino, M., additional, Gaidano, G., additional, Offidani, M., additional, el Jarari, L., additional, Gugielmelli, T., additional, Salvini, M., additional, Patriarca, F., additional, Semenzato, G., additional, Zweegman, S., additional, Di Raimondo, F., additional, Mina, R., additional, Cascavilla, N., additional, Yehuda, D.B., additional, Gambella, M., additional, Corradini, P., additional, Lokhorst, H., additional, Catalano, L., additional, Di Bartolomeo, P., additional, Hajek, R., additional, Spencer, A., additional, Boccadoro, M., additional, Sonneveld, P., additional, and Palumbo, A., additional

Published
2015
Full Text
View/download PDF

81. Safety and Efficacy of Bendamustine With Or Without Rituximab In the Treatment of Heavily Pretreated Lymphoma Patients. A Multicenter Retrospective Study

Author

Rigacci, L., Iannitto, E., Puccini, B., Antognoli, G., D'Arco, A., Orciuolo, E., Cortelazzo, S., Gaidano, G., Freilone, R., Patti, C., Zaja, F., Gobbi, M., Musto, P., Zinzani, P. L., Storti, S., Isidori, A., Bongarzoni, V., Carpaneto, A., Renzo, N. D., Musso, M., Scalabrini, D. R., Santagostino, A., Stelitano, C., Cascavilla, N., Liberati, Anna Marina, Sancetta, R., and Bosi, A.

Published
2010

82. Hema e-Chart: Italian Registry for prospective analysis of epidemiology,management and outcome of febrile events in patients with hematologicalmalignancies

Author

Pagano, L, Caira, M, Nosari, A, Rossi, G, Locatelli, F, Viale, P, Aversa, F, Collaborators: Levis A, Hema E. Chart Group I. t. a. l. y., Leoni, P, Liso, V, Baccarani, M, Cortellazzo, S, Russo, Domenico, La Nasa, G, Storti, S, Giustolisi, R, Morabito, F, Cuneo, A, Bosi, A, Capalbo, Sf, Cascavilla, N, Ghio, R, Carella, A, Brugiatelli, M, Ciceri, F, Martinelli, G, Morra, E, Pogliani, E, Mettivier, V, Carli, M, Abbadessa, V, Musso, M, Aricò, M, Lazzarino, M, Visani, G, Fioritoni, G, Di Bartolomeo, P, Vallisa, D, Petrini, M, Favre, C, Olivieri, A, Gugliotta, L, Leone, G, Amadori, S, De Rossi, G, De Fabritiis, P, Majolino, I, D'Arco, A, Lauria, F, Mazza, P, Fagioli, F, Gherlinzoni, F, Chesesi, T, and Rodeghiero, F.

Published
2010

85. Long-term Outcome of 309 Young Patients With Untreated Diffuse Large B-cell Lymphoma (dlbcl) At Poor Prognosis: A Pooled Analysis From Gimurell and Intergruppo Italiano Linfomi (iil)

Author

ANNALISA CHIAPPELLA, Cabras, M. G., Liberati, A. M., Angelucci, E., Baldini, L., Bottelli, C., Botto, B., Cascavilla, N., Ciccone, G., Cortelazzo, S., Masi, P., Falchi, L., Fioritoni, G., Frairia, C., Freilone, R., Levis, A., Orsucci, L., Parvis, C., Pogliani, E., Rota-Scalabrini, D., Salvi, F., Specchia, G., Tonso, A., Tucci, A., and Vitolo, U.

Published
2010

86. Phase 2 Open-Label study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Gladstone, D, André, Marc, Zaucha, J, Assouline, S, Bellam, N, Cascavilla , N, Jourdan, E, Panwalkar, A, Patti, C, Schulte, C, Zaja , F, Goswami, T, Elgeioushi, N, Streicher, K, Bao, H, Spaner, D, 50th Annual Meeting of the American Society if Clinical Oncology, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Gladstone, D, André, Marc, Zaucha, J, Assouline, S, Bellam, N, Cascavilla , N, Jourdan, E, Panwalkar, A, Patti, C, Schulte, C, Zaja , F, Goswami, T, Elgeioushi, N, Streicher, K, Bao, H, Spaner, D, and 50th Annual Meeting of the American Society if Clinical Oncology

Published
2014

87. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels

Author

Rossi, Giovanni, Minervini, Mm, Melillo, L, Di Nardo, Francesco, De Waure, Chiara, Scalzulli, Pr, Perla, G, Valente, D, Sinisi, N, Cascavilla, N., De Waure, Chiara (ORCID:0000-0002-4346-1494), Rossi, Giovanni, Minervini, Mm, Melillo, L, Di Nardo, Francesco, De Waure, Chiara, Scalzulli, Pr, Perla, G, Valente, D, Sinisi, N, Cascavilla, N., and De Waure, Chiara (ORCID:0000-0002-4346-1494)

Abstract

In acute myeloid leukemia (AML), the detection of minimal residual disease (MRD) as well as the degree of log clearance similarly identifies patients with poor prognosis. No comparison was provided between the two approaches in order to identify the best one to monitor follow-up patients. In this study, MRD and clearance were assessed by both multiparameter flow cytometry (MFC) and WT1 expression at different time points on 45 AML patients achieving complete remission. Our results by WT1 expression showed that log clearance lower than 1.96 after induction predicted the recurrence better than MRD higher than 77.0 copies WT1/10(4) ABL. Conversely, on MFC, MRD higher than 0.2 % after consolidation was more predictive than log clearance below 2.64. At univariate and multivariate analysis, positive MRD values and log clearance below the optimal cutoffs were associated with a shorter disease-free survival (DFS). At the univariate analysis, positive MRD values were also associated with overall survival (OS). Therefore, post-induction log clearance by WT1 and post-consolidation MRD by MFC represented the most informative approaches to identify the relapse. At the optimal timing of assessment, positive MRD and log-clearance values lower than calculated thresholds similarly predicted an adverse prognosis in AML.

Published
2014

88. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo, R., Zino, E., Vago, L., Oneto, R., Bruno, B., Pollichieni, S., Sacchi, N., Sormani, M. P., Marcon, J., Lamparelli, T., Fanin, R., Garbarino, L., Miotti, V., Bandini, G., Bosi, A., Ciceri, F., Bacigalupo, A., Fleischhauer, K., Midollo Osseo Gruppo Italiano Trapianto, D. I., Terapia Cellulare, Cellule Staminali Ematopoietiche Cse E., Italian Bone Marrow Donor Registry Collaboratori, Scalari P., Bontempelli, M., Prinoth, O., Carcassi, C., Marceno, R., Porfirio, Rombola, G., Lombardo, Ferrioli, G., Poli, F., Scalamogna, M., Mazzi, B., Rossi, F., Mascaretti, L., Albergoni, Salvaneschi, L., Salvaneschi, M., Valentini, Nesci, S., Papola, F., Scatena, Mariotti, Perrone, Laurenti, Grammatico, Paola, Mariani, M., Favoino, B., Guizzardi, Pontiero, Leoni, P., Rambaldi, A., Casini, M., Angelucci, E., Baronciani, D., La Nasa, G., Milone, G., Guidi, S., Van Lint, M. T., Dini, G., Corradini, P., Milani, R., Morra, E., Marenco, P., Deliliers, Lambretenghi G., Onida, F., Marcatti, M., Castagna, L., Pioltelli, P., Selleri, C., Zanesco, L., Scime, R., Musso, M., Alessandrino, E. P., Locatelli, F., Visani, G., Di Bartolomeo, P., Papineschi, F., Favre, C., Iori, A. P., Foa, Roberto, Locasciulli, A., Majolino, I., Majolino, P., Leone, G., Arcese, W., Cerretti, R., Carella, A. M., Cascavilla, N., Lauria, F., Mazza, P., Cerno, M., Benedetti, F., Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Lamparelli, T, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, F, Bacigalupo, A, and Fleischhauer, K

Subjects
Adult, Disease-Free Survival, Donor Selection, Female, HLA-DRB1 Chains, Hematologic Neoplasms, Humans, Italy, Male, Middle Aged, Recurrence, Registries, Retrospective Studies, Risk Factors, Survival Rate, Transplantation, Homologous, Algorithms, HLA-DR Antigens, Hematopoietic Stem Cell Transplantation, Tissue Donors, Biochemistry, Immunology, Hematology, Cell Biology, Homologous, medicine.medical_treatment, Human leukocyte antigen, Hematopoietic stem cell transplantation, Medicine, Risk factor, Survival rate, Transplantation, HLA-DPB1, business.industry, Hazard ratio, Confidence interval, business, Settore MED/15 - Malattie del Sangue
Abstract

The importance of donor-recipient human leukocyte antigen (HLA)-DPB1 matching for the clinical outcome of unrelated hematopoietic stem cell transplantation (HSCT) is controversial. We have previously described an algorithm for nonpermissive HLA-DPB1 disparities involving HLA-DPB1*0901,*1001,*1701,*0301,*1401,*4501, based on T-cell alloreactivity patterns. By revisiting the immunogenicity of HLA-DPB1*02, a modified algorithm was developed and retrospectively tested in 621 unrelated HSCTs facilitated through the Italian Registry for onco-hematologic adult patients. The modified algorithm proved to be markedly more predictive of outcome than the original one, with significantly higher KaplanMeier probabilities of 2-year survival in permissive compared with nonpermissive transplantations (55% vs 39%, P = .005). This was the result of increased adjusted hazards of nonrelapse mortality (hazard ratio [HR] = 1.74; confidence interval [CI], 1.19-2.53; P = .004) but not of relapse (HR = 1.02; CI, 0.73-1.42; P = .92). The increase in the hazards of overall mortality by nonpermissive HLA-DPB1 disparity was similar in 10 of 10 (HR = 2.12; CI, 1.23-3.64; P = .006) and 9 of 10 allele-matched transplantations (HR = 2.21; CI, 1.28-3.80; P = .004), both in early-stage and in advanced-stage disease. These data call for revisiting current HLA matching strategies for unrelated HSCT, suggesting that searches should be directed up-front toward identification of HLA-DPB1 permissive, 10 of 10 or 9 of 10 matched donors. (Blood. 2009; 114:1437-1444) RI Porfirio, Berardino/I-1988-2012

Published
2009

90. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation

Author

Crocchiolo, R, Zino, E, Vago, L, Oneto, R, Bruno, B, Pollichieni, S, Sacchi, N, Sormani, Mp, Marcon, J, Lamparelli, T, Fanin, R, Garbarino, L, Miotti, V, Bandini, G, Bosi, A, Ciceri, F, Bacigalupo, A, Fleischhauer, K, Gruppo Italiano Trapianto di Midollo Osseo, Terapia Cellulare, Cellule Staminale Ematopoietiche e., Italian Bone Marrow Donor Registry, Scalari, P, Bontempelli, M, Prinoth, O, Carcassi, C, Marcenò, R, Porfirio, Rombolà, G, Lombardo, Ferrioli, G, Poli, F, Scalamogna, M, Mazzi, B, Rossi, F, Mascaretti, L, Albergoni, Salvaneschi, L, Martinetti, M, Valentini, Renzo, Nesci, S, Papola, F, Scatena, Mariotti, Perrone, Laurenti, Grammatico, P, Mariani, M, Favoino, B, Guizzardi, Pontiero, Leoni, P, Rambaldi, A, Casini, M, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Guidi, S, Van Lint MT, Dini, G, Corradini, P, Milani, R, Morra, E, Marenco, P, Lambretenghi Deliliers, G, Onida, F, Marcatti, M, Castagna, L, Pioltelli, P, Selleri, C, Zanesco, L, Scimè, R, Musso, M, Alessandrino, Ep, Locatelli, F, Visani, G, Di Bartolomeo, P, Papineschi, Federico, Favre, C, Iori, Ap, Foà, R, Locasciulli, A, Majolino, I, Majolino, P, Leone, G, Arcese, W, Cerretti, R, Carella, Am, Cascavilla, N, Lauria, F, Mazza, P, Cerno, M, and Benedetti, F.

Published
2009

91. Efficacy, safety feasibility of 5-azacitidine for the treatment of myelodysplastic syndromes in the clinical practice: final results from a retrospective study in177 patients enrolled in the italian patient named program

Author

Musto, P, Maurillo, L, Spagnoli, A, Villani, O, Gozzini, A, Cecconi, N, D'Argenio, M, Lunghi, M, Palumbo, G, Rivellini, F, Genuardi, M, Sibilaa, S, Mele, G, Filardi, N, Sampaolo, G, Vigna, E, Pastore, D, Tonso, A, Fili, C, Candoni, A, Pollio, F, Rocco, S, Santagostino, A, Balleari, E, Cassiba, V, DELLA CIOPAA, P, Mazzone, C, Mianulli, M, Oliva, E, Ciuffreda, L, Orciuolo, E, Tatarelli, C, Russo, D, DI RENZO, N, D'Arco, A. M., Mettivier, V, Morabito, F, Cascavilla, N, Mazza, P, DI RAIMONDO, Francesco, ALOE SPIRITI, M. A., Gaidano, G, Ferrero, D, Quarta, G, Riezzo, A, Pavone, V, Specchia, G, Levis, A, Petrini, M, Olivieri, A, Ferrara, F, Voso, M. T., Leone, G, Venditti, A, and Santini, V.

Published
2009

92. Chronic myeloid leukemia as second malignancy: a retrospective multicentric study

Author

Iannito, E, Minardi, V, Barone, R, Casvavilla, N, Caracciolo, C, Ferrara, F, Franco, G, Liardo, E, Mancuso, S, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmeri, F, RUSSO ROSSI, A, Specchia, G, Tutti, D, Abbadessa, V, Iannitto, E, Cascavilla, N, DI RAIMONDO, Francesco, Palmieri, F, Turri, D, and Abbadessa, V.

Published
2009

96. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome : a study from the Gruppo Italiano Trapianto di Midollo Osseo(GITMO)

Author

Alessandrino, Ep, Della Porta MG, Bacigalupo, A, Van Lint MT, Falda, M, Onida, F, Bernardi, M, Iori, Ap, Rambaldi, A, Cerretti, R, Marenco, P, Pioltelli, P, Malcovati, L, Pascutto, C, Oneto, R, Fanin, R, Bosi, A, Collaboratori Levis, A, Bandini, G, Casini, M, Rossi, G, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Guidi, S, Corradini, P, Milani, R, Morra, E, Lambretenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scimè, R, Iannitto, E, Musso, M, Locatelli, F, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, F, Messina, G, Gugliotta, L, Foà, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, Benedetto, Boccadoro, Mario, Cerno, M, and Raimondi, R.

Subjects
Adult, Male, medicine.medical_specialty, Blood transfusion, Adolescent, medicine.medical_treatment, Immunology, World Health Organization, Biochemistry, Gastroenterology, Humans, Myelodysplastic Syndromes, Prognosis, Aged, Recurrence, Survival Rate, Classification, Blood Transfusion, Hematopoietic Stem Cell Transplantation, Middle Aged, Female, Refractory, hemic and lymphatic diseases, Internal medicine, medicine, Survival rate, Acute leukemia, Hematology, business.industry, Cancer, Cell Biology, medicine.disease, Surgery, Transplantation, Who classification, business, Settore MED/15 - Malattie del Sangue
Abstract

We evaluated the impact of World Health Organization (WHO) classification and WHO classification–based Prognostic Scoring System (WPSS) on the outcome of patients with myelodysplastic syndrome (MDS) who underwent allogeneic stem cell transplantation (allo-SCT) between 1990 and 2006. Five-year overall survival (OS) was 80% in refractory anemias, 57% in refractory cytopenias, 51% in refractory anemia with excess blasts 1 (RAEB-1), 28% in RAEB-2, and 25% in acute leukemia from MDS (P = .001). Five-year probability of relapse was 9%, 22%, 24%, 56%, and 53%, respectively (P < .001). Five-year transplant-related mortality (TRM) was 14%, 39%, 38%, 34%, and 44%, respectively (P = .24). In multivariate analysis, WHO classification showed a significant effect on OS (P = .017) and probability of relapse (P = .01); transfusion dependency was associated with a reduced OS (P = .01) and increased TRM (P = .037), whereas WPSS showed a prognostic significance on both OS (P = .001) and probability of relapse (P < .001). In patients without excess blasts, multilineage dysplasia and transfusion dependency affected OS (P = .001 and P = .009, respectively), and were associated with an increased TRM (P = .013 and P = .031, respectively). In these patients, WPSS identified 2 groups with different OS and TRM. These data suggest that WHO classification and WPSS have a relevant prognostic value in posttransplantation outcome of MDS patients.

Published
2008

98. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Author

Alessandrino, Ep, Della Porta MG, Bacigalupo, A, Van Lint MT, Falda, M, Onida, F, Bernardi, M, Iori, Ap, Rambaldi, A, Cerretti, R, Marenco, P, Pioltelli, P, Malcovati, L, Pascutto, C, Oneto, R, Fanin, R, Bosi, A, Gruppo Italiano Trapianto di Midollo Osseo, Levis, A, Bandini, G, Casini, M, Rossi, G, Angelucci, E, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Guidi, S, Corradini, P, Milani, R, Morra, E, Lambretenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scimè, R, Iannitto, E, Musso, M, Locatelli, F, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Gugliotta, L, Foà, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Cerno, M, and Raimondi, R.

Published
2008

99. BREAST CANCER RESISTANCE PROTEIN (BCRP) EXPRESSION AFFECT EVENT-FREE SURVIVAL IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Author

Gregorj, C, DE CAVE, Fabiana, Petrucci, Mt, Ricciardi, Maria Rosaria, Scerpa, Mc, Vignetti, M, Vitale, A, Meloni, G, Liso, V, Di Raimondo, F, Ferrara, F, Fabbiano, F, Camera, A, Fioritoni, G, Miraglia, E, Annino, L, Cascavilla, N, Marmont, F, Mazza, P, Perbellini, O, Cartore, N, Luppi, M, Nobile, F, Sica, S, Salvi, F, Mandelli, Franco, Foà, R., and Tafuri, Agostino

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results